- Home
- QUCY vs ENTX Comparison
QUCY vs ENTX Comparison
Compare QUCY & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QUCY | ENTX |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | Germany | Israel |
| Employees | 13 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.8M | 58.2M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | QUCY | ENTX |
|---|---|---|
| Price | $2.04 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 41.7M | 68.5K |
| Earning Date | 06-26-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | $74.34 | N/A |
| Revenue Next Year | $171.48 | N/A |
| P/E Ratio | ★ N/A | $17.43 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $0.91 |
| 52 Week High | $4.93 | $3.22 |
Technical Indicators
Market Signals| Indicator | QUCY | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 49.25 |
| Support Level | $0.38 | $1.17 |
| Resistance Level | $4.93 | $1.37 |
| Average True Range (ATR) | 0.45 | 0.06 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 6.31 | 28.57 |
Price Performance
Historical ComparisonAbout QUCY Mainz Biomed N.V. Ordinary Shares
Quantum Cyber NV is focused on building a diversified platform at the intersection of quantum computing and cybersecurity. It aims to secure critical infrastructure and data against these emerging threats.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.